^
Association details:
| Biomarker: | BCR-ABL1 T315I |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | NT-157 (STAT3 inhibitor, Insulin receptor substrate protein inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia
Published date:
01/06/2021
Excerpt:
NT157 significantly reduced colony formation of human primary CML cells with minimal effect on normal hematopoietic cells. Exposure of primary CML cells harboring BCR-ABL1T315I to NT157 resulted in increased apoptosis, reduced cell proliferation and decreased phospho-CRKL levels.
DOI:
10.1007/s10637-020-01028-8
